Reaction Details |
| Report a problem with these data |
Target | Tyrosine-protein kinase Lck |
---|
Ligand | BDBM50306682 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_767355 (CHEMBL1825467) |
---|
IC50 | <1±n/a nM |
---|
Citation | Cui, JJ; Tran-Dubé, M; Shen, H; Nambu, M; Kung, PP; Pairish, M; Jia, L; Meng, J; Funk, L; Botrous, I; McTigue, M; Grodsky, N; Ryan, K; Padrique, E; Alton, G; Timofeevski, S; Yamazaki, S; Li, Q; Zou, H; Christensen, J; Mroczkowski, B; Bender, S; Kania, RS; Edwards, MP Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem54:6342-63 (2011) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Tyrosine-protein kinase Lck |
---|
Name: | Tyrosine-protein kinase Lck |
Synonyms: | 2.7.10.2 | LCK | LCK_HUMAN | LSK | Leukocyte C-terminal Src kinase | Lymphocyte cell-specific protein-tyrosine kinase | Lymphocyte-specific protein tyrosine kinase | P56-LCK | Protein YT16 | Proto-oncogene Lck | Proto-oncogene tyrosine-protein kinase LCK | Src/Lck kinase | T cell-specific protein-tyrosine kinase |
Type: | n/a |
Mol. Mass.: | 57987.83 |
Organism: | Homo sapiens (Human) |
Description: | P06239 |
Residue: | 509 |
Sequence: | MGCGCSSHPEDDWMENIDVCENCHYPIVPLDGKGTLLIRNGSEVRDPLVTYEGSNPPASP
LQDNLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKAN
SLEPEPWFFKNLSRKDAERQLLAPGNTHGSFLIRESESTAGSFSLSVRDFDQNQGEVVKH
YKIRNLDNGGFYISPRITFPGLHELVRHYTNASDGLCTRLSRPCQTQKPQKPWWEDEWEV
PRETLKLVERLGAGQFGEVWMGYYNGHTKVAVKSLKQGSMSPDAFLAEANLMKQLQHQRL
VRLYAVVTQEPIYIITEYMENGSLVDFLKTPSGIKLTINKLLDMAAQIAEGMAFIEERNY
IHRDLRAANILVSDTLSCKIADFGLARLIEDNEYTAREGAKFPIKWTAPEAINYGTFTIK
SDVWSFGILLTEIVTHGRIPYPGMTNPEVIQNLERGYRMVRPDNCPEELYQLMRLCWKER
PEDRPTFDYLRSVLEDFFTATEGQYQPQP
|
|
|
BDBM50306682 |
---|
n/a |
---|
Name | BDBM50306682 |
Synonyms: | (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine | 3-(2,6-dichloro-3-fluorobenzyloxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine | 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine | CHEMBL601719 | CRIZOTINIB | PF-2341066 | US10370379, Crizotinib | US10543199, Compound Crizotinib | US10780082, Compound Crizotinib | US11059827, Compound Crizotinib | US11517561, Compound Crizotinib | US9126941, PF-2341066 | US9199944, Crizotinib | US9226923, Crizotinib |
Type | Small organic molecule |
Emp. Form. | C21H22Cl2FN5O |
Mol. Mass. | 450.337 |
SMILES | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl |r| |
Structure |
|